Ambiguity, Ambivalence, and Apprehensions of Taking HIV-1 Pre-exposure Prophylaxis Among Male Couples in San Francisco: a Mixed Methods Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Nov 21

PMID 23166819

Citations 62

Authors

Parya Saberi

Kristi E Gamarel

Torsten B Neilands

Megan Comfort

Nicolas Sheon

Lynae A Darbes

Mallory O Johnson

Affiliations

Soon will be listed here.

Abstract

Objective: We conducted a mixed-methods study to examine serodiscordant and seroconcordant (HIV-positive/HIV-positive) male couples' PrEP awareness, concerns regarding health care providers offering PrEP to the community, and correlates of PrEP uptake by the HIV-negative member of the couple.

Design: Qualitative sub-study included one-on-one interviews to gain a deeper understanding of participants' awareness of and experiences with PrEP and concerns regarding health care providers offering PrEP to men who have sex with men (MSM). Quantitative analyses consisted of a cross-sectional study in which participants were asked about the likelihood of PrEP uptake by the HIV-negative member of the couple and level of agreement with health care providers offering PrEP to anyone requesting it.

Methods: We used multivariable regression to examine associations between PrEP questions and covariates of interest and employed an inductive approach to identify key qualitative themes.

Results: Among 328 men (164 couples), 62% had heard about PrEP, but approximately one-quarter were mistaking it with post-exposure prophylaxis. The majority of participants had low endorsement of PrEP uptake and 40% were uncertain if health care providers should offer PrEP to anyone requesting it. Qualitative interviews with 32 men suggest that this uncertainty likely stems from concerns regarding increased risk compensation. Likelihood of future PrEP uptake by the HIV-negative member of the couple was positively associated with unprotected insertive anal intercourse but negatively correlated with unprotected receptive anal intercourse.

Conclusions: Findings suggest that those at greatest risk may not be receptive of PrEP. Those who engage in moderate risk express more interest in PrEP; however, many voice concerns of increased risk behavior in tandem with PrEP use. Results indicate a need for further education of MSM communities and the need to determine appropriate populations in which PrEP can have the highest impact.

Citing Articles

Client experiences with "Dynamic Choice Prevention," a model for flexible patient-centred HIV prevention delivery in rural Eastern Africa.

Camlin C, Arunga T, Johnson-Peretz J, Akatukwasa C, Atwine F, Onyango A J Int AIDS Soc. 2024; 27(7):e26336.

PMID: 39020454 PMC: 11254577. DOI: 10.1002/jia2.26336.

[Discrepancy between behavioral-indicated and perceived candidacy for HIV pre-exposure prophylaxis among men who have sex with men in Chengdu, China].

Lin H, Li J, Yang X, Chen X, Shi Y, Chang C Beijing Da Xue Xue Bao Yi Xue Ban. 2023; 55(3):511-520.

PMID: 37291928 PMC: 10258061.

Paying for PrEP: A qualitative study of cost factors that impact pre-exposure prophylaxis uptake in the US.

Sosnowy C, Predmore Z, Dean L, Raifman J, Chu C, Galipeau D Int J STD AIDS. 2022; 33(14):1199-1205.

PMID: 36271632 PMC: 9912748. DOI: 10.1177/09564624221132406.

PrEP in India's HIV Prevention Policy in the Era of Social Media and Sex Positivity.

Kar A, Bhugra D, Mukherjee S, Mondal A, Kumar A Cent Asian J Glob Health. 2022; 9(1):e407.

PMID: 35866086 PMC: 9295848. DOI: 10.5195/cajgh.2020.407.

Dyadic Influences on Pre-exposure Prophylaxis (PrEP) Use and Attitudes Among Male Couples.

Stephenson R, Chavanduka T, Sullivan S, Mitchell J AIDS Behav. 2021; 26(2):361-374.

PMID: 34331608 DOI: 10.1007/s10461-021-03389-4.

References

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

Barash E, Golden M . Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010; 24(11):689-91. DOI: 10.1089/apc.2010.0173. View

Johnson M, Dilworth S, Taylor J, Darbes L, Comfort M, Neilands T . Primary relationships, HIV treatment adherence, and virologic control. AIDS Behav. 2011; 16(6):1511-21. PMC: 3607313. DOI: 10.1007/s10461-011-0021-0. View

Arnold E, Hazelton P, Lane T, Christopoulos K, Galindo G, Steward W . A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One. 2012; 7(7):e40603. PMC: 3394704. DOI: 10.1371/journal.pone.0040603. View

Cassell M, Halperin D, Shelton J, Stanton D . Risk compensation: the Achilles' heel of innovations in HIV prevention?. BMJ. 2006; 332(7541):605-7. PMC: 1397752. DOI: 10.1136/bmj.332.7541.605. View

Guest G, Shattuck D, Johnson L, Akumatey B, Clarke E, Chen P . Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008; 35(12):1002-8. View

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. PMC: 3200068. DOI: 10.1056/NEJMoa1105243. View

Liu A, Vittinghoff E, Sellmeyer D, Irvin R, Mulligan K, Mayer K . Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011; 6(8):e23688. PMC: 3163584. DOI: 10.1371/journal.pone.0023688. View

Kellerman S, Hutchinson A, Begley E, Boyett B, Clark H, Sullivan P . Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr. 2006; 43(3):376-7. DOI: 10.1097/01.qai.0000234085.18914.d5. View

10.

Brooks R, Landovitz R, Kaplan R, Lieber E, Lee S, Barkley T . Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS. 2011; 26(2):87-94. PMC: 3266517. DOI: 10.1089/apc.2011.0283. View

11.

Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, Mansoor L . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74. PMC: 3001187. DOI: 10.1126/science.1193748. View

12.

Vissers D, Voeten H, Nagelkerke N, Habbema J, de Vlas S . The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One. 2008; 3(5):e2077. PMC: 2367053. DOI: 10.1371/journal.pone.0002077. View

13.

Liu A, Kittredge P, Vittinghoff E, Raymond H, Ahrens K, Matheson T . Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008; 47(2):241-7. View

14.

Desai K, Sansom S, Ackers M, Stewart S, Hall H, Hu D . Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008; 22(14):1829-39. DOI: 10.1097/QAD.0b013e32830e00f5. View

15.

Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K . Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007; 2(5):e27. PMC: 1876601. DOI: 10.1371/journal.pctr.0020027. View

16.

Abbas U, Anderson R, Mellors J . Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One. 2007; 2(9):e875. PMC: 1975470. DOI: 10.1371/journal.pone.0000875. View

17.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

18.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

19.

Paltiel A, Freedberg K, Scott C, Schackman B, Losina E, Wang B . HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009; 48(6):806-15. PMC: 2876329. DOI: 10.1086/597095. View

20.

Mimiaga M, Case P, Johnson C, Safren S, Mayer K . Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009; 50(1):77-83. PMC: 2659469. DOI: 10.1097/QAI.0b013e31818d5a27. View